William M. Sikov, MD, on the CALGB 40603 Trial

2014 San Antonio Breast Cancer Symposium

William M. Sikov, MD, of Women and Infants Hospital, discusses abstract S4-05, "Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response rates in triple-negative breast cancer after neoadjuvant chemotherapy with or without carboplatin or bevacizumab: CALGB 40603/150709 (Alliance)."

Advertisement

Advertisement



Aug
16
Today In Oncology
Drug Combination Design for Multiple Myeloma Using an AI Platform
FDA Grants Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
Definitive Pelvic Radiation Therapy Plus Chemotherapy and Survival in Newly Diagnosed Metastatic Cervical Cancer
Impact of Peer-Review Intervention on Radiotherapy Schedules for Palliative Treatment of Bone Metastases
FDA Grants Breakthrough Device Designation for Cancer Detection Liquid Biopsy
View More 
;
Advertisement
© 2018 HSP News Service, L.L.C.
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.